ATTO Attovia Therapeutics, Inc.
Fundamentals / CIK 0002058707 / USDAttovia Therapeutics, Inc. reported $411.8M in total assets through September 30, 2026 from SEC EDGAR filings.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open ATTO in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2026-- Sep 30, 2026
-
Operating Income FY 2026-- Operating profit
-
Net Income FY 2026-- GAAP bottom line
-
Diluted EPS FY 2026-- Split-adjusted
-
Free Cash Flow FY 2026-- Operating CF less CapEx
-
Cash & ST Investments Sep 30, 2026$395.9M Total debt: $3.84M
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
| Income Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $450K | -- | $360K | $0 | -- |
| Research & Development | $20.29M | $18.95M | -- | $12.32M | $13.59M | -- |
| Total Operating Expenses | $25.02M | $22.25M | -- | $15.96M | $16.62M | -- |
| Operating Income | -$25.02M | -$21.80M | -- | -$15.60M | -$16.62M | -- |
| EBITDA | -$24.82M | -$21.60M | -- | -$15.40M | -$16.42M | -- |
| Interest Income | $2.79M | $1.14M | -- | $1.85M | $2.04M | -- |
| Net Income | -$22.27M | -$20.69M | -$18.66M | -$13.78M | -$14.44M | -$15.15M |
| Basic EPS | -$0.76 | -$4.88 | -- | -$3.44 | -$3.71 | -- |
| Diluted EPS | -$0.76 | -$4.88 | -- | -$3.44 | -$3.71 | -- |
| Basic Shares Outstanding | 29.4M | 4.2M | -- | 4.0M | 3.9M | -- |
| Diluted Shares Outstanding | 29.4M | 4.2M | -- | 4.0M | 3.9M | -- |
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2026-09-30 | 2026-06-30 | 2025-12-31 |
|---|---|---|---|
| Cash & Cash Equivalents | $115.4M | $32.83M | $40.19M |
| Short-Term Investments | $280.6M | $82.30M | $112.1M |
| Cash & Short-Term Investments | $395.9M | $115.1M | $152.3M |
| Total Current Assets | $404.5M | $118.4M | $156.3M |
| Property, Plant & Equipment, Net | $3.15M | $3.34M | $3.49M |
| Other Non-Current Assets | $586K | $2.62M | $1.33M |
| Total Non-Current Assets | $7.31M | $9.95M | $9.60M |
| Total Assets | $411.8M | $128.3M | $165.9M |
| Accounts Payable | $4.22M | $6.00M | $3.55M |
| Deferred Revenue (Current) | $0 | $0 | $450K |
| Total Current Liabilities | $11.67M | $12.62M | $11.01M |
| Other Non-Current Liabilities | $672K | $678K | $755K |
| Total Non-Current Liabilities | $2.41M | $2.97M | $4.10M |
| Total Liabilities | $14.08M | $15.58M | $15.10M |
| Total Debt (incl. Leases) | $3.84M | $4.33M | $5.26M |
| Common Stock | $5.0K | $1.0K | $1.0K |
| Retained Earnings | -$172.6M | -$150.4M | -$111.0M |
| Accumulated Other Comp. Income | -$548K | -$79K | $99K |
| Total Stockholders' Equity | $397.7M | -$145.5M | -$107.4M |
| Total Equity | $397.7M | -$145.5M | -$107.4M |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
| Cash Flow Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Net Income | -$22.27M | -$20.69M | -$18.66M | -$13.78M | -$14.44M | -$15.15M |
| Depreciation & Amortization | $200K | $200K | -- | $200K | $200K | -- |
| Stock-Based Compensation | $1.63M | $692K | -- | $679K | $563K | -- |
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.
| Ratios & Growth | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Current Ratio | 34.66x | 9.39x | -- | -- | -- | -- |
| Quick Ratio | 33.93x | 9.13x | -- | -- | -- | -- |
| Debt to Equity | 0.01x | -- | -- | -- | -- | -- |
| Revenue Growth (YoY) | -100.0% | -- | -- | -- | -- | -- |